Skip to main content
OpenTrials
Completed

NCT Number: NCT06414304

Dynamics of MSI and Genomic Profile of Colorectal Cancer In the Course of Immune Checkpoint Inhibitor Therapy

Colorectal cancer (CRC) is a leading cause of cancer-related mortality worldwide. Microsatellite instability or mismatch repair deficiency occurs in 20% of CRC, and is predominantly found in non-metastatic tumors. The success of the CheckMate 142 and KEYNOTE-177 clinical trials has shifted the treatment paradigm of the MSI/dMMR CRC, which has led to the adoption of immune checkpoint inhibitors (ICI) by international treatment standards. However, despite the encouraging effects of ICI, up to 30% of patients are resistant to treatment and exhibit rapid disease progression shortly after starting ICI. On the other hand, around 30% of patients treated with ICI demonstrate prolonged responses to the treatment with a duration of response of over 40 months. Furthermore, for ~10% of patients, treatment with ICI results in pseudo-progression - a phenomenon of a short-term increase followed by the decrease of the tumor volume.

Currently, the mechanisms and biomarkers associated with the response or resistance to ICI in MSI-positive CRC are largely unknown. Select studies suggest that BRAF mutations (specifically, BRAF p.V600E) might negatively affect the patients' progression-free survival following ICI, however, these data are premature.

The primary hypothesis is that the clonal heterogeneity and the evolution of MSI status of MSI-positive CRC will play a role in the development of ICI treatment resistance. The primary objective of the study is to investigate the dynamics of MSI status in serial liquid biopsy samples from patients with MSI-positive tumors receiving ICI.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Colorectal Cancer Cancer Colon Adenocarcinoma Colonic Diseases Colonic Neoplasms Colorectal Cancer Metastatic Colorectal Neoplasms Digestive System Diseases Digestive System Neoplasms Gastrointestinal Diseases Gastrointestinal Neoplasms Genomic Instability Intestinal Diseases Intestinal Neoplasms MSI-H Colorectal Cancer Microsatellite Instability Neoplasms Neoplasms by Site Pathologic Processes Pathological Conditions, Signs and Symptoms Rectal Diseases dMMR Colorectal Cancer

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

N.N.Blokhin National Medical Research Center of Oncology, Moscow, Russia

Loading trial locations.

About this study

This is a multicenter observational trial designed to evaluate the dynamics of microsatellite instability and the genomic profiles of CRC during immune checkpoint inhibitor treatment.

Patients with MSI/dMMR-positive tumors who are candidates for the ICI treatment will be included in the study. MSI/dMMR positivity should be confirmed with polymerase chain reaction-based (PCR) assays, immunohistochemistry (IHC) or Next-generation sequencing (NGS). Treatment with any ICI will be allowed. Upon inclusion in the study, patients will be asked to provide the pre-treatment FFPE tumor and liquid biopsy (LB) samples along with LB samples on the 14th, 28th days of ICI, and at every control study. LB samples will be collected until treatment discontinuation.

The pre-treatment FFPE samples will be tested with an alternative routine method (PCR and/or IHC, depending on what method was used for initial testing), as well as with the Solo Atlas Pro NGS panel covering common cancer-related genes and short tandem repeats for MSI detection. All LB samples will be tested with the Solo Atlas Pro NGS panel. Dynamics of MSI and genomic profiles will be correlated with the treatment outcomes.

Disease response to study treatment will be evaluated by imaging methods. Response to treatment will be determined by RECIST v1.1.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male/female participants must be at least 18 years of age on the day of signing informed consent and have a histologically confirmed diagnosis of colorectal cancer.
  • Verified MSI/dMMR positivity as measured by 5-loci PCR or 4-antibody IHC.
  • The patient is scheduled to start treatment with any of the immune checkpoint inhibitors 2-4 weeks after the inclusion in the study.
  • Have provided an archival tumor tissue sample obtained prior to the start of treatment with immune checkpoint inhibitor(s). Formalin-fixed, paraffin embedded (FFPE) tissue blocks are preferred to slides.
  • Patient has to be able to provide serial blood samples during the course of treatment, as well as on every follow-up tumor scan.
  • The participant (or legally acceptable representative if applicable) provides written informed consent to participate in the trial.
  • Have measurable disease based on RECIST 1.1.
  • Have adequate organ function.

Exclusion criteria

  • Prior treatment with immune checkpoint inhibitors.
  • For female participants: pregnancy or planned pregnancy.
  • The unavailability of the tumor or serial liquid biopsy samples.

Treatment and study plan

Primary outcomes

  1. Concordance of NGS and routine methods (PCR, IHC) for MSI analysis

    Time frame: Through study completion, an average of 3 years

    Concordance will be calculated using Cohen's Kappa (κ)

Secondary outcomes

  1. Concordance of MSI in tumor tissue and liquid biopsy (ctDNA)

    Time frame: Through study completion, an average of 3 years

    Concordance will be calculated using Cohen's Kappa (κ)

  2. Qualitative and quantitative status of MSI in serial liquid biopsy (ctDNA) samples

    Time frame: Through study completion, an average of 3 years

    Liquid biopsy samples will be collected prior to the start of ICI, on the 14th and 28th days of therapy and at every follow-up tumor scan

Other outcomes

  1. Correlation of biomarkers with the treatment outcomes

    Time frame: Through study completion, an average of 3 years

    Dynamics of biomarkers in serial liquid biopsy samples will be correlated with treatment outcomes. Response to treatment will be determined by RECIST v1.1.

  2. Evaluation of the ctDNA dynamics in the course of ICI in serial plasma samples

    Time frame: Through study completion, an average of 3 years

    Dynamics of ctDNA in serial liquid biopsy samples will be correlated with treatment outcomes. Response to treatment will be determined by RECIST v1.1.

Sponsors and collaborators

Lead sponsor

OncoAtlas LLC

Industry

Collaborators

  • Moscow Multidisciplinary Clinical Center "Kommunarka"
  • N.N. Blokhin National Medical Research Center of Oncology

Registry information

Official study title

A Multi-center Observational Clinical Trial Evaluating the Dynamics of Microsatellite Instability and Genomic Profile of Colorectal Cancer in the Course of Treatment With Immune Checkpoint Inhibitors

Acronym: BLOOMSI

Important dates

Study start
2022
Primary completion
2024
Study completion
2025
First posted
May 16, 2024
Registry last updated
Jun 27, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.